United States Government Publishing Office publisher pbl distributor dst United States National Archives and Records Administration Office of the Federal Register author aut Government Organization text government publication eng FR Regulatory Information 2013_register executive 2013-03-28 article Notices D09002ee1c7fbb09e D09002ee1c7fbb14b United States Department of Health and Human Services originator org United States Government Agency or Subagency United States National Institutes of Health originator org United States Government Agency or Subagency This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of a worldwide exclusive patent license, to practice the inventions embodied in PCT patent application PCT/US2012/044421, filed June 27, 2012 (HHS Reference<greek-i> E-205-2010/2-PCT-01), which is a continuation-in-part of U.S. Application No. 13/180,111 (E-205-2010/1- US-01) which claims priority to U.S. provisional application No. 61/ 363,079 (E-205-2010/0-US-01), and entitled "Photosensitizing Antibody- Fluorophore Conjugates," to Aspyrian Therapeutics, Inc., a company incorporated under the laws of the State of Delaware, having its headquarters in San Diego, California. The United States of America is the assignee of the rights of the above invention. The field of use may be limited to "use of photosensitizing antibody-fluorophore conjugate by itself for Photoimmunotherapy (PIT), or in combination with cancer therapeutic agents, to treat cancer or pre-cancerous hyperplasia", and may be further limited to certain types of cancer and/or specific platforms. The license will include the priority case US 13/180,111, which is currently licensed to Aspyrian under an exclusive evaluation option license. The exclusive commercialization license proposed in this notice will supersede and replace the exclusive evaluation option license. 78 FR 18999 https://www.govinfo.gov/app/details/FR-2013-03-28/2013-07166 2013-07166 fr28mr13-92 4140-01-P https://www.govinfo.gov/app/details/FR-2013-03-28/2013-07166 https://www.govinfo.gov/content/pkg/FR-2013-03-28/html/2013-07166.htm https://www.govinfo.gov/content/pkg/FR-2013-03-28/pdf/2013-07166.pdf 1 p. 18999 18999 78 FR 18999 Prospective Grant of Start-Up Exclusive License: Photosensitizing Antibody-Fluorophore Conjugates for Photoimmunotherapy; Federal Register Vol. 78, Issue NOTICE 2013-07166 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health 2013-04-12 4140-01-P 2013-07166 Notice.

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of a worldwide exclusive patent license, to practice the inventions embodied in PCT patent application PCT/US2012/044421, filed June 27, 2012 (HHS Reference<greek-i> E-205-2010/2-PCT-01), which is a continuation-in-part of U.S. Application No. 13/180,111 (E-205-2010/1- US-01) which claims priority to U.S. provisional application No. 61/ 363,079 (E-205-2010/0-US-01), and entitled "Photosensitizing Antibody- Fluorophore Conjugates," to Aspyrian Therapeutics, Inc., a company incorporated under the laws of the State of Delaware, having its headquarters in San Diego, California. The United States of America is the assignee of the rights of the above invention. The field of use may be limited to "use of photosensitizing antibody-fluorophore conjugate by itself for Photoimmunotherapy (PIT), or in combination with cancer therapeutic agents, to treat cancer or pre-cancerous hyperplasia", and may be further limited to certain types of cancer and/or specific platforms. The license will include the priority case US 13/180,111, which is currently licensed to Aspyrian under an exclusive evaluation option license. The exclusive commercialization license proposed in this notice will supersede and replace the exclusive evaluation option license.

Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before April 12, 2013 will be considered. Prospective Grants of Start-Up Exclusive Licenses: Photosensitizing AntibodyFluorophore Conjugates for Photoimmunotherapy , Reichmau@mail.nih.gov Vol. 78, no. 60 Office of the Federal Register, National Archives and Records Administration 2013-03-28 continuing daily deposited born digital 323 p. Table of Contents: AE 2.7: GS 4.107: AE 2.106: KF70.A2 https://www.govinfo.gov/app/details/FR-2013-03-28 P0b002ee183fa50c2 0097-6326 0042-1219 0364-1406 769-004-00000-9 000582072 f:fr28mr13 https://www.govinfo.gov/app/details/FR-2013-03-28 https://www.govinfo.gov/content/pkg/FR-2013-03-28/pdf/FR-2013-03-28.pdf https://www.govinfo.gov/content/pkg/FR-2013-03-28/xml/FR-2013-03-28.xml fdlp 18763 19076 DGPO 2013-03-28 2024-06-03 FR-2013-03-28 machine generated eng FR FR-2013-03-28 78 60